Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Younossi ZM, et al. Among authors: knapple w. Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5. Lancet. 2019. PMID: 31813633 Free article. Clinical Trial.
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, Aguilar H, Garcia-Diaz J, Wang GP, Berry SM, Marion J, Su X, Braun T, Bancke L, Feuerstadt P. Khanna S, et al. Among authors: knapple w. Drugs. 2022 Oct;82(15):1527-1538. doi: 10.1007/s40265-022-01797-x. Epub 2022 Oct 26. Drugs. 2022. PMID: 36287379 Free PMC article. Clinical Trial.
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, Aguilar H, Garcia-Diaz J, Wang GP, Berry SM, Marion J, Su X, Braun T, Bancke L, Feuerstadt P. Khanna S, et al. Among authors: knapple w. Drugs. 2022 Oct;82(15):1539. doi: 10.1007/s40265-022-01805-0. Drugs. 2022. PMID: 36342618 Free PMC article. No abstract available.
Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA®) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial.
Khanna S, Yoho D, Van Handel D, Clark BJ, Awad T, Guthmueller B, Armandi D, Knapple W, Safdar N, Baggott B, Simon K, Feuerstadt P. Khanna S, et al. Among authors: knapple w. Ther Adv Gastroenterol. 2025 Nov 9;18:17562848251396744. doi: 10.1177/17562848251396744. eCollection 2025. Ther Adv Gastroenterol. 2025. PMID: 41230019 Free PMC article.
Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial.
Khanna S, Yoho D, Van Handel D, Clark BJ, Awad T, Guthmueller B, Armandi D, Knapple W, Safdar N, Baggott B, Simon K, Feuerstadt P. Khanna S, et al. Among authors: knapple w. Ther Adv Gastroenterol. 2025 Apr 22;18:17562848251339697. doi: 10.1177/17562848251339697. eCollection 2025. Ther Adv Gastroenterol. 2025. PMID: 40321366 Free PMC article.
PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection.
Feuerstadt P, Chopra T, Knapple W, Van Hise NW, Dubberke ER, Baggott B, Guthmueller B, Bancke L, Gamborg M, Steiner TS, Van Handel D, Khanna S. Feuerstadt P, et al. Among authors: knapple w. Clin Infect Dis. 2025 Feb 5;80(1):43-51. doi: 10.1093/cid/ciae437. Clin Infect Dis. 2025. PMID: 39180326 Free PMC article. Clinical Trial.
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.
Allegretti JR, Feuerstadt P, Knapple WL, Orenstein R, Pinton P, Sheh A, Khanna S. Allegretti JR, et al. Among authors: knapple wl. Inflamm Bowel Dis. 2025 Aug 1;31(8):2112-2122. doi: 10.1093/ibd/izae291. Inflamm Bowel Dis. 2025. PMID: 39862395 Free PMC article. Clinical Trial.
Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease.
Alkhouri N, Mantry P, Gonzalez HC, Patil R, McIntyre V, Kohli A, Rudraraju M, Kosinski JF, Vander Veen BS, Knapple WL, Ravinuthala R, Jalal PK, Satapathy SK, Bhandari BR, Christensen CJ, Ankoma-Sey V, Phan QA, Membreno FE, Lee GH, Kodali S, Mubarak A, Elbeshbeshy HA, Morin RP Jr, Hogan Ii RB, Sarles HE Jr, Le Bail B, Hiriart JB, Foucher J, Chermak F, Decraecker M, Sylvestre P, Yeh MM, Quiambao R, Mangee K, Tonascia J, Sakka M, Alkouri R, Deregnaucourt M, Bonnefont-Rousselot D, Harrison SA, Alam I, Munteanu M, Bansal M, Alazawi W, Sanyal AJ. Alkhouri N, et al. Among authors: knapple wl. J Gastrointestin Liver Dis. 2025 Dec 26;34(4):437-450. doi: 10.15403/jgld-6432. J Gastrointestin Liver Dis. 2025. PMID: 41453093 Free article.
24 results